Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID versus HEMADY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID versus HEMADY.
AMINOCAPROIC ACID vs HEMADY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by binding to plasminogen and blocking its conversion to plasmin.
HEMADY is a phytonadione (vitamin K1) formulation that promotes hepatic synthesis of clotting factors II, VII, IX, and X, reversing anticoagulation by inhibiting vitamin K epoxide reductase.
Loading dose: 4-5 g intravenously (IV) over 1 hour, followed by continuous IV infusion of 1 g/hour for 8 hours or until bleeding controlled. Oral: 1 g every hour for 8 hours, then 1 g every 2 hours for 8 additional hours.
Adult: 5 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1-3 hours) in patients with normal renal function. Prolonged in renal impairment (up to 20 hours in anuria).
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal elimination half-life is 1.2-2 hours in healthy adults; clinically relevant as it requires frequent dosing (every 4-6 hours) for sustained effect.
Primarily renal (80-90% unchanged). A small fraction (<5%) is excreted as metabolites. No significant biliary/fecal elimination.
Primarily renal excretion of unchanged drug (70-80%), with 20-30% metabolized and excreted as inactive metabolites in urine; less than 5% eliminated in feces via biliary secretion.
Category C
Category C
Antifibrinolytic
Antifibrinolytic